CLINICAL_TRIALS
trial_result
· 2021-04-26
Clinical Trial Update: A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma [Phase 2]
Summary
Phase 2 trial update for CaBozantinib in metastatic/metastatic renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED